PT - JOURNAL ARTICLE AU - Oka, Akira AU - Hadano, Shinji AU - Ueda, Mahoko Takahashi AU - Nakagawa, So AU - Komaki, Gen AU - Ando, Tetsuya TI - Rare <em>CRHR2</em> and <em>GRM8</em> variants identified as candidate factors associated with eating disorders in Japanese patients AID - 10.1101/2023.08.24.23294455 DP - 2023 Jan 01 TA - medRxiv PG - 2023.08.24.23294455 4099 - http://medrxiv.org/content/early/2023/08/25/2023.08.24.23294455.short 4100 - http://medrxiv.org/content/early/2023/08/25/2023.08.24.23294455.full AB - Eating disorders (EDs) are a type of psychiatric disorder characterized by pathological eating and related behavior and considered to be highly heritable. The purpose of this study was to explore rare variants expected to display biological functions associated with the etiology of EDs. We performed whole exome sequencing (WES) of affected sib-pairs corresponding to disease subtype through their lifetime and their parents. From those results, rare single nucleotide variants (SNVs) concordant with sib-pairs were extracted and estimated to be most deleterious in the examined families. Two non-synonymous SNVs located on corticotropin releasing hormone receptor 2 (CRHR2) and glutamate metabotropic receptor 8 (GRM8) were identified as candidate disease susceptibility factors. The SNV of CRHR2 was included within the cholesterol binding motif of the transmembrane helices region, while the SNV of GRM8 was found to contribute to hydrogen bonds for an α-helix structure. CRHR2 plays important roles in the serotoninergic system of dorsal raphe nuclei, which is involved with feeding and stress-coping behavior. Moreover, GRM8 modulates glutamatergic neurotransmission, and is also considered to have effects on dopaminergic and adrenergic neurotransmission. Further investigation regarding the biological function of these variants may provide an opportunity for elucidate the pathogenesis of EDs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by JSPS KAKENHI (16K09275 and 23390191).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Upon approval of the experimental procedures from the relevant ethical committees at the National Institute of Mental Health, National Center of Neurology and Psychiatry (number: A2013-054) and Tokai University (number: 14I-60), we obtained written informed consent in accordance with the Declaration of Helsinki from 30 sib pairs and their family members prior to collection of DNA samples.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.